First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer

Launched by RELAY THERAPEUTICS, INC. · Jan 18, 2022

Keywords

ClinConnect Summary

This clinical trial is testing a new drug called RLY-2608, which is designed to target a specific genetic mutation (PIK3CA) found in some solid tumors, including certain types of breast cancer. The study aims to find out the highest dose of RLY-2608 that patients can tolerate, how safe it is, and whether it can help shrink tumors. Participants will receive RLY-2608 either on its own or in combination with another medication called fulvestrant, particularly if they have advanced breast cancer that is not responding to standard treatments.

To be eligible for this trial, patients need to have a confirmed PIK3CA mutation and specific types of advanced solid tumors or metastatic breast cancer that cannot be treated with conventional therapies. This includes patients who have already received certain types of cancer treatments. Throughout the trial, participants will be monitored closely for any side effects and to assess how well the treatment is working. If you or a loved one is interested, it’s important to discuss this with a healthcare provider to see if this study is a good fit.

Gender

ALL

Eligibility criteria

• • Key Inclusion Criteria
• • Patient has ECOG performance status of 0-1
• • One or more documented primary oncogenic PIK3CA mutation(s) in blood and/or tumor per local assessment
• • - Other potentially oncogenic PIK3CA mutations may be considered but must be approved by the Sponsor prior to enrollment.
• • Part 1 - Ability to provide archived tumor tissue or be willing to undergo pretreatment tumor biopsy to assess PIK3CA status retrospectively Part 2 - Submit tumor tissue prior to study drug initiation for determination of PIK3CA mutation retrospectively.
• • Key Inclusion for RLY-2608 Single Agent Arm
• • \[For Part 1\]: Evaluable disease per RECIST v1.1
• • \[For Part 2\]: Measurable disease per RECIST v1.1
• • Disease that is refractory to standard therapy, intolerant to standard therapy, or has declined standard therapy.
• • Part 1- histologically or cytologically confirmed diagnosis of unresectable or metastatic solid tumor
• * Part 2 - Unresectable or metastatic solid tumor with PIK3CA mutation(s) and one of the following tumor types:
• • Group 1: clear cell ovarian cancer Group 2: head and neck squamous cell carcinoma Group 3: cervical cancer Group 4: other solid tumors, excluding colorectal, clear cell ovarian, head and neck squamous cell, and cervical cancers Group 5: unresectable or metastatic solid tumors with PIK3CA double mutations In addition, the SRC (with Sponsor approval) may choose to open additional group(s) of 20 participants to study the clinical activity, safety, and PK/PD in other specified solid tumor types.
• • Key Inclusion for Combination Arms
• • \[For Part 1 and Part 2\]: Evaluable disease per RECIST v1.1
• • \[For Part 1 and Part 2\]: Male or female with histologically or cytologically confirmed diagnosis of HR+, HER2- unresectable or metastatic breast cancer that is not amenable to curative therapy. Females may be postmenopausal, premenopausal, or perimenopausal. Premenopausal or perimenopausal females must have a histologically or cytologically confirmed diagnosis of HR+ HER2- advanced or metastatic breast cancer that is not amenable to curative therapy and must have been previously treated with GnRH agonist at least 4 weeks prior to start of study drug
• * \[For Part 1 and Part 2\]: Had previous treatment for breast cancer with:
• • 1. ≤1 line of chemotherapy in the metastatic setting
• • 2. ≥1 CDK4/6 inhibitor in either the adjuvant and/or metastatic setting
• • 3. ≥1 antiestrogen therapy in either adjuvant and/or metastatic setting, including, but not limited to, selective estrogen-receptor degraders (eg, fulvestrant), selective estrogen receptor modulators (eg, tamoxifen), and aromatase inhibitors (AI) (letrozole, anastrozole, exemestane), and
• • 4. ≥1 PARP inhibitor, if appropriate, if documented germline BRCA1/2 mutation Note: Systemic local, loco-regional, or adjuvant treatment with chemotherapy and PARP inhibitors is not to be included in enumeration or previous treatment
• • \[For RLY-2608 + fulvestrant arm; Part 2, Group 2\]: Received prior treatment with a PI3Kα or AKT inhibitor and discontinued the inhibitor due to intolerance and not disease progression, where intolerance is defined as treatment discontinuation due to treatment related AE (eg. hyperglycemia, rash, diarrhea, stomatitis) other than severe hypersensitivity reaction and/or life-threatening reactions, such as anaphylaxis and Stevens-Johnson syndrome.
• • \[For triple combination arms; Part 1 only\]: Participants who had previous treatment for breast cancer with PI3Kα or AKT inhibitors will be considered.
• • \[For triple combination arms with ribociclib or palbociclib; Part 1 only\]: endometrial cancer may be enrolled.
• • Key Exclusion Criteria
• • Prior treatment with PI3Kα, AKT, or mTOR inhibitors (except for RLY-2608 + fulvestrant arm, Part 2, Group 2; and triplet combinations, Part 1).
• • Type 1 or Type 2 diabetes requiring antihyperglycemic medication, or fasting plasma glucose ≥140 mg/dL and glycosylated hemoglobin (HbA1c) ≥7.0%.
• • History of hypersensitivity to PI3K inhibitors. For combination arms only: hypersensitivity to fulvestrant, palbociclib, ribociclib, and/or PF-07220060, as appropriate for the combination.
• • Past medical history of or ongoing ILD, or pneumonitis requiring intervention. Participants with past history of resolved Grade 1 pneumonitis may be considered, except in triple combination arms.
• Any of the following cardiac criteria:
• • Mean resting corrected QT interval (QTc) \>470 msec. For triple combination arm with ribociclib: Mean QTcF ≥450 msec.
• • Patient has a history of prolonged QT syndrome or torsades de pointes. Patient has a familial history of prolonged QT syndrome.
• • Clinically significant, uncontrolled cardiovascular disease
• • CNS metastases or primary CNS tumor that is associated with progressive neurologic symptoms